Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Targeting Inflammation and Alloimmunity in Heart Transplant Recipients With Tocilizumab (RTB-004)

Trial Profile

Targeting Inflammation and Alloimmunity in Heart Transplant Recipients With Tocilizumab (RTB-004)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Feb 2019

At a glance

  • Drugs Tocilizumab (Primary) ; Methylprednisolone; Mycophenolate sodium; Prednisolone; Tacrolimus; Tacrolimus; Tacrolimus
  • Indications Heart transplant rejection
  • Focus Therapeutic Use
  • Most Recent Events

    • 03 Dec 2018 Status changed from not yet recruiting to recruiting.
    • 07 Nov 2018 Planned initiation date changed from 1 Oct 2018 to 1 Nov 2018.
    • 12 Sep 2018 Planned initiation date changed from 1 Sep 2018 to 1 Oct 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top